key: cord-0815766-n0bb1bbo
authors: Toobian, Daniel; Ghosh, Pradipta; Katkar, Gajanan D.
title: Parsing the Role of PPARs in Macrophage Processes
date: 2021-12-22
journal: Front Immunol
DOI: 10.3389/fimmu.2021.783780
sha: 757f8386f88089e264ee24c05510ce7ee37bb344
doc_id: 815766
cord_uid: n0bb1bbo

Cells are richly equipped with nuclear receptors, which act as ligand-regulated transcription factors. Peroxisome proliferator activated receptors (PPARs), members of the nuclear receptor family, have been extensively studied for their roles in development, differentiation, and homeostatic processes. In the recent past, there has been substantial interest in understanding and defining the functions of PPARs and their agonists in regulating innate and adaptive immune responses as well as their pharmacologic potential in combating acute and chronic inflammatory disease. In this review, we focus on emerging evidence of the potential roles of the PPAR subtypes in macrophage biology. We also discuss the roles of dual and pan PPAR agonists as modulators of immune cell function, microbial infection, and inflammatory diseases.

Peroxisome proliferator activated receptors (PPARs) are ligand-dependent transcription factors that are structurally conserved members of the nuclear receptor superfamily (1) . PPARs influence a variety of cell signals including cellular differentiation and development (2) (3) (4) , lipid metabolism (5), the insulin signaling network (6) , homeostasis (7) and tumorigenesis (2, 3, 8) . In 1960, scientists showed an increased number of peroxisomes in the livers of rats treated with hypolipidemic drugs. A decade later, this increase was attributed to certain members of the nuclear receptor family. In 1990, Issemann and Green cloned these receptors for the first time and demonstrated that hepatocarcinogens promote the proliferation of peroxisomes in rodents through these receptors, and thus named them Peroxisome Proliferator Activated Receptors (PPARs) (9) . Three PPAR isoforms have been identified thus far: PPARa, PPARb/d and PPARg. They each have distinct patterns of function and tissue distribution, and are expressed in various cell types including immune cells (6, 10, 11) , epithelial cells (12) and endothelial cells (13, 14) . All PPARs utilize a common domain organization ( Figure 1A) with a slightly variable amino-terminal that contributes to transcriptional activation function, and a central highly conserved DNA binding domain that contains a zinc motif (15) . A ligand-binding domain at the carboxy-terminal end confers their ligand-binding property, regulates ligand-dependent transcriptional activation and repression functions, and contributes to receptor homo-or heterodimerization ( Figures 1B, C) (16, 17) .

PPARg is the most extensively characterized and researched member of the PPAR subfamily and consists of two isoforms, PPARg1 and PPARg2, that are expressed mainly in adipose tissue. They mediate adipocyte differentiation by regulating the expression of genes that are involved in lipid metabolism and insulin signaling (18) . PPARa is the second most studied PPAR, expressed mainly in liver and immune cells which regulate lipid catabolism, especially during fasting conditions (19) . The third is PPARd, (aka PPARb) which is highly active in skeletal muscle where it is also involved in regulating fatty acid catabolism (20, 21) . PPARd activation also increases insulin sensitivity, improves lipid homeostasis, and prevents weight gain. Though PPARs are extensively studied, their role in molecular and cellular signaling in immune cells has limited understanding.

PPARs also regulate the functions of the innate immune system such as macrophage function and differentiation (5, 17, 22, 23) . Thus, there has been substantial interest in understanding and defining the functions of PPARs and their agonists in regulating gene expression in macrophage biology and how that relates to acute and chronic inflammatory diseases (22) . Few studies attempted to discuss the role of PPARs in macrophage function, and the discussion is generally limited to PPARg (6, 10, 22, 24) . Since all three isoforms of PPARs regulate each other's expression through feedback loops, it is worthwhile to understand their role together. In this review, we begin with a brief introduction of PPAR signaling and mechanism, and then highlight recent developments that provide insight into how isoforms of PPAR and their agonists can regulate several steps involved in the initiation, proliferation, and resolution of inflammatory responses in macrophages, especially in the context of microbial infection and inflammatory diseases.

hormone response elements (PPREs) present in the vicinity of target genes. PPARs predominantly bind as heterodimers with retinoid X receptors (RXRs), either in presence or absence of ligands ( Figure 1C) , to stimulate transcription activity (23, 25) For example, PPARa increases expression of carnitine palmitoyl transferase (CPT)-I, an enzyme located in the mitochondrial outer membrane controlling fatty acid b-oxidation (23, 25) ,. Additionally, PPARs negatively regulate target genes by constitutively binding, along with nuclear co-repressors, to the PPREs of target genes which often function as transcriptional repressors in absence of ligands ( Figure 1C ). For example, NCoR and SMRT decrease transcriptional activity of PPARg thus preventing iNOS induction by LPS. Also, PPARs bind directly to transcriptional factors involved in inflammation including NF-kB and AP1, inhibiting their transcriptional activity. This phenomenon is termed as 'trans-repression' (Figures 1C, 2A , B) (23, 25) .

Trans-activation is mainly regulated by recruiting coactivators ( Figure 1C) , which enhance activation of PPARregulated genes. For example, PPAR coactivator-1a (PGC-1a)

is a co-activator of both PPARa and PPARg. Repression, trans-repression, and trans-activation mechanisms of transcriptional control of PPARs has been extensively studied and reviewed elsewhere. In the following section, we discuss recent progress in understanding how PPARs and their agonists regulate the metabolic and inflammatory signaling of macrophages in response to infection and inflammatory diseases.

Inflammation is a host response that targets invading infectious agents and tissue injury through recruitment of immune cells and repair machinery. Macrophages detect pathogen associated molecular patterns (PAMPs) present on microbes using pattern recognition receptors (PRR) (26) (27) (28) . For example, toll-like receptor 4 (TLR4) is a PRR that recognizes lipopolysaccharides (LPS) present on gram-negative bacteria cell walls (28) . In addition to recognizing diverse microbial components, many toll-like receptors also detect endogenous danger signals associated with tissue injuries and inflammatory diseases. Upon microbial invasion or purified ligand stimulation, TLRs promote rapid activation of major signal dependent transcription factors: nuclear factor-kB (NF-kB), activator protein 1 (AP1), and interferon regulatory factors (IRFs) (10, 28) (Figure 2A) . These transcription factors work together to rapidly induce genes that trigger the initial inflammatory response, promote antimicrobial activity, and activate development of acquired immunity. It is important for macrophages to sustain sufficient inflammation to kill invading microbes. This sustained inflammation is maintained by several cytokines upregulated during initial stimulation which promote a forward transcriptional loop due to the autocrine and paracrine effects of cytokines (26, 29, 30) . However, sustained inflammation can lead to collateral tissue damage (30) . Therefore, negative feedback loops are essential to limit the extent of inflammation and promote resolution.

Tissue-resident macrophages support embryonic development and tissue homeostasis. During early embryonic stage premacrophage are colonize entire embryo and rapidly diversify transcription programme depending on tissue specific transcription factor need. PPARs, most notably PPARg, play a role in defining the lineage of tissue-resident macrophages, whereas other PPAR isoforms contribute lesser. PPARg is required for the transcriptional modulation in regulating differentiation of pre-macrophages to alveolar macrophages (31, 32) , Kupffer cells (33) , adipose-associated macrophages, and intestinal macrophages ( Figure 3 ). It has been demonstrated that granulocyte-macrophage colony-stimulating factor (GM-CSF) promotes the expression of PPARg, one of the major transcription factors regulating differentiation of premacrophage to alveolar macrophages (31, 32) . Although, molecular mechanism underlying role PPARs in lineage determination of tissue macrophage deserves to be explored, several studies, in the past have reported the role of PPARs in macrophage polarization.

Macrophages are phagocytic innate immune cells, whose functions include scavenging microbes and apoptotic and necrotic cells, as well as playing a role in lipid homeostasis and tissue remodeling. Macrophages possess functional heterogeneity, in that they uptake different functions depending on signaling factors and metabolic changes (26) (27) (28) 30) . For example, upon sensing invading pathogens and Th-1 cytokines such as IFNg, macrophages assume immune reactive form (pro-inflammatory/classical activation state, M1) to phagocytose pathogens. In contrast, after encountering Th-2 cytokines such as IL4 and IL13, macrophages assume immune tolerant form (anti-inflammatory/alternative activation state, M2) to help with tissue repair and angiogenesis in injured tissues (27, 30) . Impaired functions of both immune reactive and immune tolerant states of macrophages could lead to host tissue damage and development of chronic disease (10, 30, (34) (35) (36) .

PPARg activation suppresses the immunoreactive state of macrophage as reported by suppression of immune reactive cytokine markers such as NOS2, TNFa, IL6, IL1b and MCP1 in murine macrophages (37) , whereas its activation promotes immunotolerant state markers such as CD36, IL13, Arg1, Ym1, Fizz1, CD206, IL4, and IL10 in murine macrophages (22, (38) (39) (40) (41) . PPARg deficient mouse macrophages also showed an increase in Th1 cytokines such as TNF-a, IL1-b, IL-6, IL-12 and a reduction of Th2 cytokine IL10 when induced with LPS (42) . PPARg also inhibits the expression of HIF1a, which plays key role in inducing the immune reactive phenotype, and promotes Arginase 1 expression, which is a hallmark marker of the immune tolerant macrophage, in mice (43) . The evidence makes it clear that PPARg is in charge of, or at least promotes, the immune tolerant state of macrophages. This is further evidenced by how PPARg responds to infection in vivo.

As stated, the function of immune tolerant macrophages includes post-infection repair, which includes the cleanup of debris (44) . PPARg agonists have been shown to increase Fcg receptor-mediated opsonized phagocytosis in murine alveolar macrophages (45, 46) demonstrating a possible pathway in which PPARg controls the cleanup process. In terms of repair, one study showed that PPARg deficient mice had an increase in pulmonary collagen deposition following influenza infection (47) , demonstrating PPARg's role is proper tissue repair post- infection. Again, PPARg shows itself to be a good promoter of the immune tolerant macrophage phenotype. PPARg can also affect macrophage polarization in a ligandindependent manner through trans-activation. For example, after alternative activation through exposure to IL4, macrophages displayed a remodeled and more accessible chromatin profile, an upregulation of PPARg, and no changes in RXR levels. Upon subsequent stimulation with IL4, PPARg bound to DNA independently of ligands through the recruitment of P300 and RAD21, leading to further anti-inflammatory activity (48) . Additionally, PPARg transcriptional activity has been induced in a ligand-independent manner by insulin and Cpeptide. Neither insulin nor C-peptide affected PPARg transcription levels. Also, the addition of PPARg antagonist GW9662 had no effect on insulin and C-peptide stimulation of PPARg, confirming its ligand-independent activity (49) .

As for PPARa, one study demonstrated that activating human cells with PPARa agonist WY-14 643 led to an upregulation of Th1 cytokines such as IL-1b-induced inflammatory cytokines (50) . Furthermore, extracts from PPARa deficient mice demonstrated higher levels of IL13 and GATA-3 (51), which is a vital transcription factor for Th2 differentiation (52) . This demonstrates how PPARa promotes the immune reactive state through inhibiting the immune tolerant state of macrophages. However, PPARa has also been shown to be involved in tissue repair. Activation of PPARa using WY 14,643 led to a reduction of acute injury and vascular leakage in perforated mouse lungs (53) . Additionally, PPARa activation contributes to rapid repair of intestinal epithelium during SIV infection in macaque models (54) . While this does seem contradictory, there is nothing in these studies that suggest that these repairs are related to macrophage polarization, so the idea that PPARa promotes the immune reactive macrophage phenotype is not ruled out.

Out of all the three members of the PPAR family, PPARd has the least amount of research conducted on it. There is evidence relating PPARd to the promotion of Th2 cytokines, suggesting its essential relationship with alternative activation of macrophages, however. IL-13 and IL-4 are examples of Th2 cytokines that become active through STAT6 activation (55) . Additionally, adipocytes secrete Th2 cytokines involved in alternative activation, as macrophages incubated with adipocyte conditioned medium (CM) displayed an inhibition in proinflammatory Th1 cytokines such as MCP-1 and TNFa while displaying an upregulation of immune tolerant marker genes such as Mgl1 and Mgl2 (56) . When PPARd-deficient mice were incubated with adipocyte CM, there was an inhibition of STAT6 activity, inhibiting alternative activation of macrophages. There was also an inhibition of transcription of immune tolerant markers Mgl1, Mgl2, and Mrc2 and an upregulation of Th1 cytokines such as MCP-1, TNFa, and IL-6 (57). This study suggests that PPARd expression in macrophages is essential for adipocyte-induced activation of immune tolerant state of macrophages. This hypothesis is further corroborated by other studies. GW501516, a PPARd agonist, inhibits transcription of Th1 cytokines such as IL-6, IL1b, TNFa, and NF-kB as well as neutrophil and macrophage infiltration in mice (58) . PPARd activation has also been shown to suppress IFNg in mice (58, 59) . Another study directly demonstrated that transferring PPARddeficient bone marrow into wild type mice led to an inhibition of alternative activation of macrophages (60) . We conclude that PPARd, similarly to PPARg, promotes the immune tolerant phenotype and inhibits the immune reactive phenotype of macrophages, while PPARa promotes the immune reactive phenotype while inhibiting the immune tolerant phenotype. The members of the PPAR family indirectly regulate each other on their effects on macrophage differentiation through competing cytokines.

Upon infection, macrophages surge at the place of infection and assume a pro-inflammatory, immune reactive state. Immune reactive macrophages are programmed for phagocytosis and killing of the invading pathogen by producing large amount of reactive oxygen species (ROS). Since this infectious environment is low in oxygen, immune reactive macrophages program themselves to survive in low oxygen (hypoxic) conditions (61) . Within immune reactive macrophages, both aerobic glycolysis and pentose phosphate pathways are induced upon activation ( Figure 4 ). Glycolysis promotes glucose uptake to produce pyruvate ( Figure 4) . However, under hypoxic conditions, NADH cannot be oxidized to NAD+, a required electron acceptor for the further oxidation of pyruvate. Therefore, in hypoxic conditions, pyruvate is first reduced to lactate, accepting electrons from NADH, and thereby regenerating the NAD+ needed for glycolysis to continue (62) . In the immune reactive macrophage's mitochondria, the electron transport chain is dampened, promoting production of mitochondrial reactive oxygen species (mtROS) due to incomplete electron transfers ( Figure 4) . Additionally, induction of pentose phosphate pathways in immune reactive macrophages generates more NADPH, which is needed for the NADPH oxidase to generate cytosolic ROS and nitric oxide (63) . PPARs modulate both glycolysis and NADPH oxidase induced ROS (Figure 4) . PPARg diminishes glycolysis in mice by promoting expression of 6-Phosphofructo-2-Kinase/ Fructose-2,6-Biphosphatase 3 (PFKFB3), which in gluconeogenesis pathway, converts fructose-2,6-bis phosphate to fructose-6-phosphate and increases accumulation of fructose-6-phosphate ( Figure 4 ) (64). This indicates that PPARg prevents macrophages from polarizing towards the glycolysis dependent immune reactive state, further confirming its anti-inflammatory effect on macrophages. Interestingly, PPARa, but not PPARg, is essential for NADPH oxidase induced ROS generation in both humans and mice (65) . This is further evidence that PPARa contributes to immune reactive macrophage polarization (66) .

Immune tolerant macrophages, on the other hand, obtain their energy from fatty acid oxidation and oxidative phosphorylation for tissue repair and tissue remodeling (67) . In addition, macrophages can induce the constituent electron transport chain, which is required for oxidative phosphorylation and drives pyruvates into the Krebs cycle ( Figure 4) . Both PPARa and PPARg promote the gene expression of several molecules/enzymes involved in oxidation of fatty acid. For example, PPARa and PPARg, in humans, promote expression of mitochondrial fatty acid transporter carnitine palmitoyltransferase 2 (CPT2) and the hydroxyacyl-coenzyme A (CoA) dehydrogenase trifunctional multienzyme complex subunit beta (HADHB) (68) , which catalyzes the final step of b-oxidation ( Figure 4) .

Considering PPARa promotes fatty acid oxidation, it may seem as though PPARa is anti-inflammatory. However, the promotion of fatty acid oxidation through PPARa also leads to its inhibition through proinflammatory phospholipid byproducts. PPARa has been shown to promote leukotriene B4 (LTB4) synthesis through b-oxidation in rats. Interestingly, LTB4 and other fatty acid derived molecules are ligands for PPARa, thus this feedback loop promotes their own catabolism and leads to resolution of inflammation (69) (Figure 4) . Even though PPARa contributes to fatty acid oxidation, it only does so to regulate and inhibit itself to allow for less inflammation. Taken together, it emerges again that PPARa is essential for promoting the immune reactive state of macrophage whereas PPARg is essential for promoting the immune tolerant macrophage. PPARa demonstrates its ability to regulate its own proinflammatory abilities through self-inhibition when inflammation resolution is necessary.

When it comes to bacterial infection, PPARg activation appears to correlate with poor outcome. PPARg activation in both humans and mice has been shown to decrease the number of neutrophils and macrophages as well as compromise bacterial clearance, which could worsen complications such as influenzaassociated pneumonia (70) . Several studies have shown that known PPARg agonists contribute to caspase-associated apoptosis of monocytes, T cells, and B cell progenitors (71) (72) (73) . PPARg has also been shown to attenuate neutrophil migration and activation (74) . This may explain how PPARg can cause immunosuppression to the extent of increasing risk of infection. This is further corroborated by a study that demonstrated how PPARg knockout mice had an increased effector response when infected with E. coli (75) . This may also explain why PPARg agonists have shown an increased risk in cardiovascular dysfunction in humans (76) , as there are many species of bacteria that can increase risk of cardiovascular disease. PPARg can certainly be seen as a therapeutic target for infection and immune related diseases but should be done so with the consideration of its indication of poor prognosis through inhibition of bacterial clearance.

On the other hand, PPARa activation has been shown to be protective against bacterial infections. Infection with Francisella tularensis heavily upregulates fatty acid metabolism, which we already know is regulated by the PPARa pathway (77). This may be indirect evidence that infection with F. tularensis leads to PPARa activation. PPARa activation using gemfibrozil has been shown to decrease the bacterial load of Mycobacterium tuberculosis infected mice while also inhibiting M. abscessus induced hypersecretion of pro-inflammatory cytokines (78) . One more study using mice demonstrated similar results using Pseudomonas aeruginosa (79) . Another study demonstrated that PPARa-deficient mice have a decreased survival rate during bacterial sepsis as well as impaired liver metabolism (80) . Again, in contrast to PPARg, PPARa demonstrates a pro-inflammatory phenotype, with it promoting cells' abilities to kill bacteria, especially considering we previously mentioned PPARa's ability to induce NADPH oxidase formation of ROS, which is essential for bacterial clearance.

As for PPARd, there is unfortunately a lack of direct evidence on its impact on bacterial clearance. Considering we do know its similarities to PPARg in its promotion of immune tolerant phenotype macrophages, we can hypothesize that its activation also inhibits bacterial clearance. However, more studies would need to be conducted to confirm this.

In infection, too much inflammation can devastate the body. For example, influenza infection can lead to a "cytokine storm", a hyper-induction of immune response that can lead to complications and lung pathogenesis (81) . Considering excessive inflammation is tied to influenza related mortality, PPARg has been considered as a therapeutic target to limit such harmful inflammation (82) . In a recent study, it was demonstrated that in mouse alveolar macrophages, PPARg mRNA levels were reduced after influenzaA infection and respiratory syncytial virus infection (24) . In contrast, the spike protein of SARS-CoV-2 upregulates PPARg in macrophage-like RAW264.7 cells (83) . In another independent study, infection with MERS-CoV upregulated PPARg in human macrophages (84) . It appears that PPARg is upregulated in certain viral infections while downregulated in other viral infections. Regardless, PPARg plays a significant role in the prognosis of viral infections in general.

One study demonstrated that PPARg reduced the secretion of influenza-induced proinflammatory cytokines TNF-a, IL-8, and RANTES in humans (85) . PPARg activation also leads to decreased mortality in obese mice infected with influenza (86) . Furthermore, HIV infection in mice also leads to the hyperinduction of proinflammatory genes such as TNFa, IL-1b, IFNg, CCL2, CCL3, CXCL10, and iNOS, all of which has been shown to be attenuated using PPARg agonists rosiglitazone and pioglitazone (87) . While PPARg activation leads to poor prognosis in bacterial infection, it apparently leads to good prognosis in viral infection through its inhibition of hyperimmune response.

PPARa activation contributes to rapid repair of intestinal epithelium during SIV infection in macaque models (54) . Interestingly, certain viral infections, such as Zika virus, have been shown to modulate and dysregulate PPARa signaling pathways in human cells (88) . The core protein of hepatitis C virus (HCV) was also found to inhibit PPARa expression in humans (89) . Another study confirmed that both PPARa and PPARg are downregulated during HCV infection, and then further downregulated during co-infection with HIV in humans (90) . Furthermore, activation of PPARa has been shown to inhibit STING activation of type I interferons as well as increase herpesvirus replication in infected mouse cells (91) . It appears that PPARa activation and an increase in viral load and pathogenesis are heavily correlated, again showing an inverse relationship between bacterial infection prognosis and viral infection prognosis. PPAR agonists and antagonists may be key therapeutic strategies depending on the type of infection.

Inflammatory bowel diseases (IBD) including Crohn's disease (CD) and ulcerative colitis (UC) negatively impact the quality of life of millions of people (92) . CD consists of inflammation of the mouth, anus, and intestines, while UC consists of inflammation in the mucosal layer of the colon (93) . Common proinflammatory cytokines are associated with IBD such as TNFa, IL-1b, IL-6, IFNg, and IL-12 (94) which are predominantly secreted by inflammatory immune cells including neutrophils and macrophages. Unsurprisingly, anti-inflammatory drugs are a common treatment for IBD.

Colon RNA seq data revealed the fact that both PPARa and PPARg are down regulated during IBD disease progression (95, 96) . Considering PPARg demonstrates anti-inflammatory abilities and is highly expressed in the intestines (97), many researchers see PPARg as a good treatment candidate target. Rosiglitazone, pioglitazone, troglitazone and AS002, known PPARg agonists, have demonstrated protection and recovery from pathogenic inflammation in colitis mouse models (98, 99) ( Table 1) . However, several PPARg agonists have failed in clinical trials ( Table 1) .

Regarding PPARa, there is conflicting evidence on its role in IBD. One study showed how the PPARa-UGT pathway increased de novo bile acid synthesis, exacerbating mouse model colitis (131) . Another study used a recombinant protein (rSj16) taken from bacteria and demonstrated its effects on inhibiting PPARa as well as protecting against DSS-induced colitis in mice (132) . When mouse models were treated with fenofibrate, PPARa activation increased in parallel to colonic inflammation (133) . Although, it should be noted that fenofibrates alter many different metabolic pathways (134) . One the other hand, several studies conclude the opposite. When mice were treated with PPARa agonist Wy-14643, there was a decrease in susceptibility to colitis (135) . Additionally, verbascoside (VB) acts as a collector of intracellular ROS, reducing experimental colitis. PPARa-KO mice showed weaker VBmediated anti-inflammatory activity compared to wild type, suggesting PPARa's protective role against IBD (136) . Also, in PPARa-KO mice, innate immune cells decreased production of IL-22 and antimicrobial peptides RegIIIb and RegIIIg as well as calprotectin. This led to commensal dysbiosis as well as an increased tolerance for gut bacteria that release proinflammatory cytokines (137) . Finally, an additional study demonstrated that dexamethasone induced anti-inflammatory activity is weakened in PPARa-KO mice (138) .

Knowledge of PPARd and its role in IBD is severely limited. One study showed that dual activation of PPARd and PPARg using conjugated linoleic acid (CLA) downregulated both TNFa and NFkb activation while upregulating TGF-b1 as well as protecting against DSS and CD4 induced colitis in mice (139) . However, another study demonstrated that PPARd upregulates COX-2 in mouse gut epithelial cells, leading to an increase in macrophage-produced proinflammatory cytokines and increased the risk of colonic inflammation (140) .

In our previous study we demonstrated that activation of PPARa or PPARg individually is not enough for protection against Citrobacter-induced colon infection in mice. However, a dual activation of both PPARa and PPARg using a balanced dual agonist protected mice form Citrobacter-induced colon infection (141) .

Taking all this information, it appears that the use of antiinflammatory PPARg agonists prevent excessive inflammation in colon. However, its prolonged use could lead to polarization of gut macrophages towards an immunotolerant state which eventually help the survival and replication of pathogenic gut bacteria and inflate the development of IBDs. Additionally, continuous use of PPARa agonists alone causes excessive activation of NADPH oxidase and mitochondrial dependent ROS production, potentially leading to collateral host tissue damage and inflammation. Therefore, balanced activation of both PPARg and PPARa is the key to treat the IBD disease and might be help prevent IBD disease progression, combining the pro-inflammatory effects of PPARa and the antiinflammatory effects of PPARg.

Atherosclerosis is the leading cause of the development of cardiovascular diseases. During hyperlipidemic conditions, lipids sneak into the subendothelial layer of the aortic wall, where oxidation of lipid alters it to form oxidized LDL (oxLDL). Macrophages scavenge on oxLDL to process it. However, excess oxLDL promotes oxLDL accumulation in macrophages, leading to foam cell formation and atherosclerosis development. PPARa activation was shown to promote low density lipid (LDL) oxidation in humans and mice (65) , as ROS can be responsible for the oxidation of LDL and PPARa increases ROS levels through NADPH oxidase. PPARa activation has also been shown to inhibit LPS activation of iNOS (65) , the inducible enzyme that produces nitric oxide (NO). Normally, NO is responsible for overall cardiovascular health (142) , vasodilation (143) , as well as inhibition of LDL oxidation (144) . However, in the presence of an excess of superoxides, NO can react with the superoxides to create peroxynitrite, a reactive peroxide that can lead to ROS and RNS (reactive nitrogen species) (145) . Interestingly, oxLDL has been shown to activate PPARa (65) . So far, PPARa has been described as pro-inflammatory, yet it also appears to demonstrate self-regulatory abilities. PPARa increases ROS/superoxide levels, as previously stated, and uses oxLDL as a signal to know that such an increase has taken place. In an effort to protect the cell from self-destruction from the creation of too much ROS, PPARa disables an alternate pathway that superoxides can interact with to create even more potentially harmful reactive species, namely the iNOS activation pathway ( Figure 5) .

Polyphenols, such as punicalagin, gallic acid, and ellagic acid, derived from fruits such as pomegranates, have been shown to activate PPARg activity (146) . Activation of PPARg using these polyphenols increases transcription and protein activity of Paraoxonase 1 (PON1) in HuH7 hepatocyte cells (146) . There are also several studies that demonstrate a correlation between an activation of PPARg, using agonists such as rosiglitazone and several different statins, and an increase in PON1 activity (147) (148) (149) (150) (151) (Table 1) . Once PON1 forms, it associates with high-density lipids (HDL) (152) , where is performs several protective functions, such as preventing lipid hydroperoxide formation on HDL as well as protecting the activity of lecithin-cholesterol acyltransferase (LCAT) (153) , an enzyme important for HDL antioxidant function and preventing oxidative stress (154) . Furthermore, HDL-associated PON1 has been shown to prevent oxidation of low-density lipids (LDL) in humans (155, 156) . When LDL is oxidized (oxLDL), lipoperoxides and thiobarbituric acid reactive substances are formed, which can cause oxidative damage. PON1 was shown to inhibit accumulation of these harmful agents in mice (157) . By preventing the oxidation of LDL, PON1 and PPARg demonstrate anti-atherosclerotic properties (158) . Furthermore, monocyte chemoattractant protein-1 (MCP-1), which is produced from oxLDL, binds to oxLDL in order to attract macrophages to uptake them. PON1 inhibits this production as seen in human endothelial cells (158) . Interestingly, oxLDL also inhibits activity of PON1 in humans (159) , possibly in an effort to equilibrate oxidation. Naturally derived polyphenols have also been shown to increase transcription of paraoxonase 2 (PON2) through activation of PPARg. This was further confirmed as known PPARg agonist rosiglitazone was shown to stimulate PON2 expression in mouse macrophages (160) . PON2 potentially plays a protective role in the prevention of superoxide and reactive oxygenated species (ROS). Normally within complex 3 of the electric transport chain (ETC), coenzyme Q10 (Q10) donates an electron from QH2 to cytochrome C. Q10's transition phase, ubisemiquinone, is rather unstable and can sometimes donate the electron to oxygen instead of cytochrome C, when treated with ETC inhibitors, forming superoxides, leading to ROS and oxidative stress (141) . Interestingly, PON2 is not only localized within the inner mitochondrial membrane where it is associated with complex 3, but it also binds with high affinity to Q10 (161) . Furthermore, PON2 deficient mice were shown to have increased mitochondrial oxidative stress, decreased complex 1 and 3 activities, decreased oxygen consumption, and decreased ATP production (161) , demonstrating that lacking PON2 interrupts the ETC. All this information suggests that PON2 associates with Q10, protecting it from destabilization and preventing it from donating electrons to oxygen to form superoxides and ROS. This would mean PON2, and therefore PPARg, plays an antioxidant role in preventing oxidative stress through the Q cycle pathway.

PPARg can also inhibit the production of ROS and oxidative stress in other, more direct ways as well. When mouse macrophages were incubated with PPARg agonist prostaglandin D2 metabolite 15-deoxy-D12,14prostaglandin J2 (15d-PGJ2), the activities of proinflammation transcription factors transcription factors AP-1, STAT and NF-kB were antagonized (162) . These three proteins act as transcription factors for nitric oxide synthase (iNOS), therefore PPARg inhibits the transcription of iNOS and the accumulation of nitric oxide (163) . Induction of iNOS has been shown to increase ROS levels in mouse RAW264. 7 macrophages as well (164) . PPARg again demonstrates a suppressive role against oxidative stress and ROS (Figure 6 ), which is why it has been such a common target for anti-atherosclerotic therapy. However, considering the previously stated increase in risk of infection, a dual PPARa/g agonist would be a safer approach, especially considering both PPARg and PPARa inhibit iNOS related ROS production.

PPARg antagonists such as GW9662 and T0070907 have been shown to inhibition the uptake of apoptotic cells (165) . As stated before, immune-suppressive macrophage function includes postinfection repair and cleanup and debris (44) . This is further evidence that PPARg promotes the immune-suppressive phenotype of macrophages. PPARg antagonist use have also been a strategy for therapy, although less common agonist usage. For example, PPARg antagonists have shown an ability to increase insulin-sensitivity and as well as inhibit adipocyte differentiation, lipid metabolism, and lipid accumulation in mouse models (166) (167) (168) (169) . PPARg antagonist Gleevec has also been shown to increase the browning of white adipose tissue in both humans and mice (170) . Because of this, PPARg antagonists have been seen as a potential therapy for type 2 diabetes and obesity. PPARg antagonists have also been seen as a potential (171). This is also because fatty acid metabolism is associated with tumorigenesis (172). They have especially been seen as therapy for cancers in areas with high amounts of adipose tissue such as breast cancer (173, 174) . As for PPARa antagonists, there is less research on their therapeutic potential. They have mostly been seen has a potential therapy for different types of cancer. One study demonstrated that PPARa antagonist NXT629 induces apoptosis in chronic lymphocytic leukemia cells using mouse models (175) . Another study using mouse models demonstrated that PPARa antagonist GW6471 attenuates tumor growth in renal cell carcinoma (176) .

PPARd antagonists have even less research backing them, but they are generally seen the same way as PPARa antagonists in their use in cancer therapy (177) . One study even demonstrates anti-psoriasis therapy in mice (178) . Overall, PPAR antagonists are an interesting strategy for therapy, however, there does not seem to be significant clinical research on them ( Table 2) . While there is evidence of their therapeutic benefits, single PPAR antagonists pose the same potential risks of single PPAR agonists. Activating or inhibiting only one member of the PPAR subfamily creates the risk of an overactive or underactive immunity. There is not much research on dual or pan PPAR antagonists, but the use of single PPAR antagonists should be done with these potential risks in mind.

In terms of clinical study and treatment, more are leaning towards dual and pan agonists for the PPAR family. While several have been discontinued, several new agonists are in preclinical and clinical trials ( Table 1) . We have demonstrated the dueling relationship between PPARg and PPARa in terms of macrophage differentiation, bacterial and viral clearance, IBD, and atherosclerosis. A PPARg/a dual agonist seems to be more promising in terms of therapeutics and activation of both receptors would counter the each other's side effects while still providing better pharmacological effects (184) . Another notable example is how PPARg agonists have been used as a therapeutic drug for increasing insulin resistance in diabetic patients as well as lipid metabolism in patients with atherosclerosis. However, clinical trials were halted when patients developed increased risks for congenital heart disease (76) . While studies of PPARg/a agonists in relation to diabetes have been done before (185), there has been a greater focus in more recent years on how these dual agonists can treat diabetes with greater efficacy while also limiting the risk of heart failure (76), utilizing both pro and antiinflammatory effects to our advantage. Another approach for the same problem is using PPARa/d dual agonists, such as GFT505, which have been shown to treat type 2 diabetes while altogether avoiding the cardiovascular risk of PPARg agonists (186) . The same PPARa/d dual agonist has also been shown to demonstrate hepatoprotective properties (187) . Pan PPAR agonists are being studied for many different conditions such suppressing inflammation and increasing lipid oxidation (188) , protecting against metabolic disorders and fibrosis (189), and even angiogenesis in ischemic mice (190) . Regarding direct crosstalk between PPARs, there is unfortunately little evidence. Only one study provided evidence for direct crosstalk, demonstrating that PPARg inhibits PPARd while PPARa inhibits PPARd as PPARd activates PPARa (191) . There is more evidence regarding indirect crosstalk, such as how all three PPARs inhibit NF-kB signaling and function as previously mentioned. There is also how PPARd increases COX-2 transcription while both PPARg and PPARa inhibit it. However, looking at indirect relationships gives little insight into direct crosstalk, as there are many interfering pathways. More studies must be done on how specific PPAR activation/inhibition affects other PPAR transcription and activity in order to gain greater insight on the outcomes of PPAR agonists as well as dual and pan agonists.

The Nuclear Receptor Superfamily: The Second Decade

Peroxisome Proliferator-Activated Receptor (PPAR) Gamma: Adipose-Predominant Expression and Induction Early in Adipocyte Differentiation

Forming Functional Fat: A Growing Understanding of Adipocyte Differentiation

The Nuclear Receptor PPAR Gamma Selectively Inhibits Th17 Differentiation in a T Cell-Intrinsic Fashion and Suppresses CNS Autoimmunity

PPARs and Lipid Ligands in Inflammation and Metabolism

Macrophage-Specific PPARgamma Controls Alternative Activation and Improves Insulin Resistance

Distinct But Complementary Contributions of PPAR Isotypes to Energy Homeostasis

Role of PPAR Receptor in Different Diseases and Their Ligands: Physiological Importance and Clinical Implications

Activation of a Member of the Steroid Hormone Receptor Superfamily by Peroxisome Proliferators

Inflammation, and Insulin Resistance

The Role of T Cell PPAR Gamma in Mice With Experimental Inflammatory Bowel Disease

Expression of PPAR Gamma in Intestinal Epithelial Cells Is Dispensable for the Prevention of Colitis by Dietary Abscisic Acid

Hypotension, Lipodystrophy, and Insulin Resistance in Generalized PPARgamma-Deficient Mice Rescued From Embryonic Lethality

PPARgamma in Endothelial Cells Influences High Fat Diet-Induced Hypertension

Structure of the Intact PPAR-Gamma-RXR-Nuclear Receptor Complex on DNA

The Peroxisome Proliferator-Activated Receptor Interacts With the Retinoid X Receptor In Vivo

The Mechanisms of Action of PPARs

Expression of Peroxisome Proliferator-Activated Receptor-Gamma1 and Peroxisome Proliferator-Activated Receptor-Gamma2 in Visceral and Subcutaneous Adipose Tissue of Obese Women

The Peroxisome Proliferator-Activated Receptors: Ligands and Activators

Peroxisome Proliferator-Activated Receptors and Their Ligands: Nutritional and Clinical Implications-A Review

Quantitative Expression Patterns of Peroxisome Proliferator-Activated Receptor-Beta/Delta (PPARbeta/delta) Protein in Mice

Control of Macrophage Activation and Function by PPARs

Combinatorial Roles of Nuclear Receptors in Inflammation and Immunity

PPAR-g in Macrophages Limits Pulmonary Inflammation and Promotes Host Recovery Following Respiratory Viral Infection

Nuclear Receptor Transrepression Pathways That Regulate Inflammation in Macrophages and T Cells

Molecular Control of Activation and Priming in Macrophages

Environment Drives Selection and Function of Enhancers Controlling Tissue-Specific Macrophage Identities

IL-10-Producing Intestinal Macrophages Prevent Excessive Antibacterial Innate Immunity by Limiting IL-23 Synthesis

Heterogeneity in Tissues: Phenotypic Diversity and Functions

Specification of Tissue-Resident Macrophages During Organogenesis

Induction of the Nuclear Receptor PPAR-g by the Cytokine GM-CSF Is Critical for the Differentiation of Fetal Monocytes Into Alveolar Macrophages

PPAR-Gamma Activation Is Associated With Reduced Liver Ischemia-Reperfusion Injury and Altered Tissue-Resident Macrophages Polarization in a Mouse Model

Regulation of Macrophage Immunometabolism in Atherosclerosis

Macrophages in Intestinal Homeostasis and Inflammation

Self-Maintaining Gut Macrophages Are Essential for Intestinal Homeostasis

The In Vitro and In Vivo Anti-Inflammatory Effects of a Phthalimide PPAR-Gamma Agonist

PPARgamma Activation Primes Human Monocytes Into Alternative M2

Macrophages With Anti-Inflammatory Properties

PPARgamma Promotes Mannose Receptor Gene Expression in Murine Macrophages and Contributes to the Induction of This Receptor by IL-13

Procyanidin B2 Activates PPARgamma to Induce M2 Polarization in Mouse Macrophages

Peroxisome Proliferator-Activated Receptor-Gamma Modulates the Response of Macrophages to Lipopolysaccharide and Glucocorticoids

Mutual Inhibitory Mechanisms Between PPARgamma and Hif-1alpha: Implication in Pulmonary Hypertension

Macrophages in Skeletal Muscle Aging

Stimulatory Effects of Peroxisome Proliferator-Activated Receptor-Gamma on Fcgamma Receptor-Mediated Phagocytosis by Alveolar Macrophages

Immunomodulatory Role of PPAR-Gamma in Alveolar Macrophages

Macrophage PPAR-Gamma Suppresses Long-Term Lung Fibrotic Sequelae Following Acute Influenza Infection

The Nuclear Receptor PPARgamma Controls Progressive Macrophage Polarization as a Ligand-Insensitive Epigenomic Ratchet of Transcriptional Memory

Ligand-Independent Activation of Peroxisome Proliferator-Activated Receptor-Gamma by Insulin and C-Peptide in Kidney Proximal Tubular Cells: Dependent on Phosphatidylinositol 3-Kinase Activity

WY-14 643, a Selective PPAR{alpha} Agonist, Induces Proinflammatory and Proangiogenic Responses in Human Ocular Cells

Peroxisome Proliferator-Activated Receptors Alpha and Gamma Down-Regulate Allergic Inflammation and Eosinophil Activation

The Transcription Factor GATA-3 Is Necessary and Sufficient for Th2 Cytokine Gene Expression in CD4 T Cells

Peroxisome Proliferator-Activated Receptor-Alpha Reduces Inflammation and Vascular Leakage in a Murine Model of Acute Lung Injury

PPARalpha-Targeted Mitochondrial Bioenergetics Mediate Repair of Intestinal Barriers at the Host-Microbe Intersection During SIV Infection

Alternative Activation of Macrophages

Adipocyte-Derived Th2 Cytokines and Myeloid PPARdelta Regulate Macrophage Polarization and Insulin Sensitivity

Peroxisome Proliferator-Activated Receptor Beta/Delta Agonist Suppresses Inflammation and Promotes Neovascularization

PPARdelta Regulates Multiple Proinflammatory Pathways to Suppress Atherosclerosis

PPARgamma and PPARdelta Negatively Regulate Specific Subsets of Lipopolysaccharide and IFN-Gamma Target Genes in Macrophages

Alternative M2 Activation of Kupffer Cells by PPARdelta Ameliorates Obesity-Induced Insulin Resistance

Inflammatory Response of Macrophages in Infection

Glycolysis. Treasure Island (FL: StatPearls

Diverse Roles of Mitochondria in Immune Responses: Novel Insights Into Immuno-Metabolism

Disruption of Inducible 6-Phosphofructo-2-Kinase Impairs the Suppressive Effect of PPARgamma Activation on Diet-Induced Intestine Inflammatory Response

Peroxisome Proliferator-Activated Receptor Alpha Induces NADPH Oxidase Activity in Macrophages, Leading to the Generation of LDL With PPAR-Alpha Activation Properties

NADPH Oxidases Are Essential for Macrophage Differentiation

New Insights on the Role of Lipid Metabolism in the Metabolic Reprogramming of Macrophages

Control of Human Carnitine Palmitoyltransferase II Gene Transcription by Peroxisome Proliferator-Activated Receptor Through a Partially Conserved Peroxisome Proliferator-Responsive Element

The PPARalpha-Leukotriene B4 Pathway to Inflammation Control

Peroxisome Proliferator-Activated Receptor Gamma (PPAR) Suppresses Inflammation and Bacterial Clearance During Influenza-Bacterial Super-Infection

Pioglitazone Induces Apoptosis of Macrophages in Human Adipose Tissue

Peroxisome Proliferator Activator Receptor-Gamma Agonists and 15-Deoxy-Delta(12,14)(12,14)-PGJ(2) Induce Apoptosis in Normal and Malignant B-Lineage Cells

Activation-Induced PPARgamma Expression Sensitizes Primary Human T Cells Toward Apoptosis

Sepsis-Induced Inhibition of Neutrophil Chemotaxis Is Mediated by Activation of Peroxisome Proliferator-Activated Receptor-{Gamma}

The Role of Peroxisome Proliferator-Activated Receptor Gamma in Immune Responses to Enteroaggregative Escherichia Coli Infection

Modulation of Hepatic PPAR Expression During Ft LVS LPS-Induced Protection From Francisella Tularensis LVS Infection

The Peroxisome Proliferator-Activated Receptor Alpha-Agonist Gemfibrozil Promotes Defense Against Mycobacterium Abscessus Infections

Involvement of TLR4 and PPAR-Alpha Receptors in Host Response and NLRP3 Inflammasome Activation, Against Pulmonary Infection With Pseudomonas Aeruginosa

Hepatic PPARalpha Is Critical in the Metabolic Adaptation to Sepsis

The Cytokine Storm of Severe Influenza and Development of Immunomodulatory Therapy

PPAR-Gamma Activation as an Anti-Inflammatory Therapy for Respiratory Virus Infections

Spike Protein of SARS-CoV-2 Activates Macrophages and Contributes to Induction of Acute Lung Inflammations in Mice

Middle East Respiratory Syndrome Corona Virus Spike Glycoprotein Suppresses Macrophage Responses via DPP4-Mediated Induction of IRAK-M and Pparg

PPARg Agonist Reduces The Inflammatory Cytokine But Not The Interferon Response To Influenza In Human Alveolar Macrophages

Targeting Peroxisome Proliferator-Activated Receptor-Gamma Decreases Host Mortality After Influenza Infection in Obese Mice

Peroxisome Proliferator-Activated Receptor-Gamma Agonists Exhibit Anti-Inflammatory and Antiviral Effects in an

Dysregulation of Ephrin Receptor and PPAR Signaling Pathways in Neural Progenitor Cells Infected by Zika Virus

Impaired Expression of the Peroxisome Proliferator-Activated Receptor Alpha During Hepatitis C Virus Infection

Hepatic Peroxisome Proliferator-Activated Receptor Gamma and alpha-mRNA Expression in HCV-Infected Adults Is Decreased by HIV Co-Infection and is Also Affected by Ethnicity

Metabolic Control of Viral Infection Through PPAR-a Regulation of STING Signaling

Inflammatory Bowel Disease

A Review of the Diagnosis, Prevention, and Treatment Methods of Inflammatory Bowel Disease

Cytokines in Inflammatory Bowel Disease

Peroxisome Proliferator-Activated Receptor-Gamma Is Downregulated in Ulcerative Colitis and Is Involved in Experimental Colitis-Associated Neoplasia

Peroxisome Proliferator-Activated Receptors Family Is Involved in the Response to Treatment and Mild Clinical Course in Patients With Ulcerative Colitis

The Organization, Promoter Analysis, and Expression of the Human PPARgamma Gene

A Novel Topical PPARgamma Agonist Induces PPARgamma Activity in Ulcerative Colitis Mucosa and Prevents and Reverses Inflammation in Induced Colitis Models

Attenuation of Colon Inflammation Through Activators of the Retinoid X Receptor (RXR)/peroxisome Proliferator-Activated Receptor Gamma (PPARgamma) Heterodimer. A Basis for New Therapeutic Strategies

Omega-3 Fatty Acids Regulate Gene Expression Levels Differently in Subjects Carrying the PPARalpha L162V Polymorphism

Novel Peroxisome Proliferator-Activated Receptor Alpha/ Gamma Dual Agonist With Efficacious Glucose and Lipid-Lowering Activities

Comparative Molecular Profiling of the PPARalpha/gamma Activator Aleglitazar: PPAR Selectivity, Activity and Interaction With Cofactors

Rational Targeting of Peroxisome Proliferating Activated Receptor Subtypes

Netoglitazone Is a PPAR-Gamma Ligand With Selective Effects on Bone and Fat

The PPARs: From Orphan Receptors to Drug Discovery

The PPARalpha/ gamma Dual Agonist Chiglitazar Improves Insulin Resistance and Dyslipidemia in MSG Obese Rats

Novel Ppara/g Agonist With Predominant Ppara Activity, Shows Lipid-Lowering and Insulin-Sensitizing Effects in Preclinical Models

Bavachinin, as a Novel Natural Pan-PPAR Agonist, Exhibits Unique Synergistic Effects With Synthetic PPAR-Gamma and PPAR-Alpha Agonists on Carbohydrate and Lipid Metabolism in Db/Db and Diet-Induced Obese Mice

Physiological Characterization of a Novel PPAR Pan Agonist, 2-(4-(5,6-Methylenedioxybenzo[D]Thiazol-2-Yl)-2-Methylphenoxy)-2-Methylpropanoic Acid (MHY2013)

PPARalpha-UGT Axis Activation Represses Intestinal FXR-FGF15 Feedback Signalling and Exacerbates Experimental Colitis

Rsj16 Protects Against DSS-Induced Colitis by Inhibiting the PPAR-Alpha Signaling Pathway

PPARalpha-Dependent Exacerbation of Experimental Colitis by the Hypolipidemic Drug Fenofibrate

A Review of Its Pharmacodynamic and Pharmacokinetic Properties and Therapeutic Use in Dyslipidaemia

PPARalpha Contributes to Colonic Protection in Mice With DSS-Induced Colitis

PPAR-Alpha Contributes to the Anti-Inflammatory Activity of Verbascoside in a Model of Inflammatory Bowel Disease in Mice

Homeostatic PPARalpha Signaling Limits Inflammatory Responses to Commensal Microbiota in the Intestine

Peroxisome Proliferator-Activated Receptor-Alpha Modulates the Anti-Inflammatory Effect of Glucocorticoids in a Model of Inflammatory Bowel Disease in Mice

Activation of PPAR Gamma and Delta by Conjugated Linoleic Acid Mediates Protection From Experimental Inflammatory Bowel Disease

Peroxisome Proliferator-Activated Receptor Delta Promotes Colonic Inflammation and Tumor Growth

Ubisemiquinone Is the Electron Donor for Superoxide Formation by Complex III of Heart Mitochondria

Nitric Oxide in the Pathogenesis of Vascular Disease

Role of Nitric Oxide in Inflammatory Diseases

Inhibition of Low-Density Lipoprotein Oxidation by Nitric Oxide. Potential Role in Atherogenesis

Nitric Oxide, and Peroxynitrite: Redox Pathways in Molecular Medicine

Paraoxonase 1 (PON1) Expression in Hepatocytes Is Upregulated by Pomegranate Polyphenols: A Role for PPAR-Gamma Pathway

Atorvastatin Effect on High-Density Lipoprotein-Associated Paraoxonase Activity and Oxidative DNA Damage

Simvastatin Attenuates Cardiopulmonary Bypass-Induced Myocardial Inflammatory Injury in Rats by Activating Peroxisome Proliferator-Activated Receptor Gamma

Effect of Simvastatin Therapy on Paraoxonase Activity and Related Lipoproteins in Familial Hypercholesterolemic Patients

Rosiglitazone Modulates Fasting and Post-Prandial Paraoxonase 1 Activity in Type 2 Diabetic Patients

But No Benefit for Abdominal Aortic Aneurysms

PPARs in Regulation of Paraoxonases: Control of Oxidative Stress and Inflammation Pathways

Paraoxonase 1 Overexpression in Mice and its Effect on High-Density Lipoproteins

Increased Low-Density Lipoprotein Oxidation and Impaired High-Density Lipoprotein Antioxidant Defense Are Associated With Increased Macrophage Homing and Atherosclerosis in Dyslipidemic Obese Mice: LCAT Gene Transfer Decreases Atherosclerosis

Paraoxonase Active Site Required for Protection Against LDL Oxidation Involves its Free Sulfhydryl Group and Is Different From That Required for its Arylesterase/Paraoxonase Activities: Selective Action of Human Paraoxonase Allozymes Q and R

Paraoxonase Prevents Accumulation of Lipoperoxides in Low-Density Lipoprotein

Paraoxonases 1, 2, and 3, Oxidative Stress, and Macrophage Foam Cell Formation During Atherosclerosis Development

Paraoxonase-1 Inhibits Oxidised LDL-Induced MCP-1 Production by Endothelial Cells

Human Serum Paraoxonase (PON 1) is Inactivated by Oxidized Low Density Lipoprotein and Preserved by Antioxidants

Macrophage Paraoxonase 2 (PON2) Expression Is Up-Regulated by Pomegranate Juice Phenolic Anti-Oxidants via PPAR Gamma and AP-1 Pathway Activation

Paraoxonase 2 Deficiency Alters Mitochondrial Function and Exacerbates the Development of Atherosclerosis

The Peroxisome Proliferator-Activated Receptor-Gamma Is a Negative Regulator of Macrophage Activation

Peroxisome Proliferator-Activated Receptor Gamma-Dependent Repression of the Inducible Nitric Oxide Synthase Gene

Induction of Inducible Nitric Oxide Synthase Increases the Production of Reactive Oxygen Species in RAW264

PPARgamma-Dependent Regulation of Human Macrophages in Phagocytosis of Apoptotic Cells

Betulinic Acid Is a PPARgamma Antagonist That Improves Glucose Uptake

A New Selective Peroxisome Proliferator-Activated Receptor Gamma Antagonist With Antiobesity and Antidiabetic Activity

Identification of a Proliferator-Activated Receptor-Gamma Antagonist for the Treatment of Type 2 Diabetes Mellitus

A Synthetic Antagonist for the Peroxisome Proliferator-Activated Receptor Gamma Inhibits Adipocyte Differentiation

PPARgamma Antagonist Gleevec Improves Insulin Sensitivity and Promotes the Browning of White Adipose Tissue

Potential of Peroxisome Proliferator-Activated Receptor Gamma Antagonist Compounds as Therapeutic Agents for a Wide Range of Cancer Types

Tumour Fatty Acid Metabolism in the Context of Therapy Resistance and Obesity

GW9662, a Potent Antagonist of PPARgamma, Inhibits Growth of Breast Tumour Cells and Promotes the Anticancer Effects of the PPARgamma Agonist Rosiglitazone, Independently of PPARgamma Activation

The Pparg Antagonist T0070907 Suppresses Breast Cancer Cell Proliferation and Motility via Both Pparg-Dependent and -Independent Mechanisms

A Selective Novel Peroxisome Proliferator-Activated Receptor (PPAR)-Alpha Antagonist Induces Apoptosis and Inhibits Proliferation of CLL Cells In Vitro and In Vivo

PPARalpha Inhibition Modulates Multiple Reprogrammed Metabolic Pathways in Kidney Cancer and Attenuates Tumor Growth

A Novel Peroxisome Proliferator-Activated Receptor Delta Antagonist, SR13904, Has Anti-Proliferative Activity in Human Cancer Cells

Skin-Targeted Inhibition of PPAR Beta/Delta by Selective Antagonists to Treat PPAR Beta

Psoriasis-Like Skin Disease In Vivo

Phase 1/1b Multicenter Trial of TPST-1120, a Peroxisome Proliferator-Activated Receptor Alpha (Ppara) Antagonist as a Single Agent (SA) or in Combination in Patients With Advanced Solid Tumors

Inhibition of Peroxisome-Proliferator-Activated Receptor (PPAR)alpha by MK886

T0070907, a PPAR Gamma Inhibitor, Induced G2/M Arrest Enhances the Effect of Radiation in Human Cervical Cancer Cells Through Mitotic Catastrophe

Artificial Intelligence-Rationalized Balanced Ppara/g Dual Agonism Resets the Dysregulated Macrophage Processes in Inflammatory Bowel Disease

Dual Peroxisome Proliferator-Activated Receptor-Alpha/ Gamma Agonists : In the Treatment of Type 2 Diabetes Mellitus and the Metabolic Syndrome

The Dual Peroxisome Proliferator-Activated Receptor Alpha/Delta Agonist GFT505 Exerts Anti-Diabetic Effects in Db/Db Mice Without Peroxisome Proliferator-Activated Receptor Gamma-Associated Adverse Cardiac Effects

Hepatoprotective Effects of the Dual Peroxisome Proliferator-Activated Receptor Alpha/Delta Agonist, GFT505, in Rodent Models of Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis

A PPAR Pan Agonist, MHY2013 Alleviates Age-Related Hepatic Lipid Accumulation by Promoting Fatty Acid Oxidation and Suppressing Inflammation

The New-Generation Pan-Peroxisome Proliferator-Activated Receptor Agonist IVA337 Protects the Liver From Metabolic Disorders and Fibrosis

Pan-PPAR Agonist, Bezafibrate, Restores Angiogenesis in Hindlimb Ischemia in Normal and Diabetic Rats

Peroxisome Proliferator-Activated Receptor (PPAR)-Gamma Positively Controls and PPARalpha Negatively Controls Cyclooxygenase-2 Expression in Rat Brain Astrocytes Through a Convergence on PPARbeta/delta via Mutual Control of PPAR Expression Levels

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest

PG and GK conceived and designed the project. DT, PG, and GK drafted, reviewed, and edited the manuscript. All authors contributed to the article and approved the submitted version.

This work was supported by the National Institute of Health Grants, AI155696 and AI141630 (to PG). GK was supported through The American Association of Immunologists Intersect Fellowship Program for Computational Scientists and Immunologists.